Psychiatr. praxi. 2012;13(4):166-168

Depression in anxiety disorders

prof.MUDr.Eva Češková, CSc.
CEITEC &ndash, MU, Psychiatrická klinika LF MU a FN Brno

The co-occurrence of depression and anxiety can be perceived as a depressive episode with prominent anxiety symptoms (anxious

depression) or as comorbid anxiety and depression. Furthermore, there is a question whether anxious depression represents an individual

category. Some preclinical and clinical studies suggest that anxious depression has certain specific features. Anxious depression is

associated with a worse outcome, chronicity, and poor treatment response. Concerning the treatment in both depressive and anxiety

disorders, the first and second choice drugs are antidepressants with preference for newer antidepressants such as SSRIs and SNRIs.

In nonresponding patients, augmentation with atypical antipsychotics comes to the fore. Some patients with anxious depression need

a lower starting dose, slower escalation, a higher end dose, and a longer duration of treatment and/or augmentation.

Keywords: comorbidity, anxious depression, antidepressants, atypical antipsychotics

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Depression in anxiety disorders. Psychiatr. praxi. 2012;13(4):166-168.
Download citation

References

  1. Kosová J. Deprese s úzkostí a poruchami spánku Med Pro Praxi 2007? 4: 169-171.
  2. Maršálek M. Komorbidita deprese a úzkosti. Psychiatrie 2003? 7: 203-213.
  3. Fava M, Uebelacker LA, Albert E, et al. Major depressive subtypes and treatment response. Biol Psychiatry 1997? 42: 568-576. Go to original source... Go to PubMed...
  4. Fava M, Rush AJ, Albert JE, et al. Difference in treatment and outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008? 165: 242-251. Go to original source... Go to PubMed...
  5. Coryell W, Fiedorowicz JG, Salomon D, et al. Effects on anxiety on the long-term course of depressive disorders. Br J Psychiatry 2012; 200: 210-215. Go to original source... Go to PubMed...
  6. Coryell W, Endicott J, Andreasen NC, et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988? 145: 293-300. Go to original source... Go to PubMed...
  7. Kessler RC, Stang PE, Wittchen HU, et al. Lifetime panicdepression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 1998? 55: 801-808. Go to original source... Go to PubMed...
  8. Dindo L, Corryell W. Comorbid major depression and panic disorder: signifikance of temporal sequencing to familial transmission. J Afffect Disord 2004; 82: 11923. Go to original source... Go to PubMed...
  9. Kessler RC, Perglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005? 62: 593-602. Go to original source...
  10. Domschke K, Dannlowski U, Hohol C, et al. Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010? 20: 301-309. Go to original source...
  11. Neumann ID, Werner G, Homberg JR, et al. Animal models of depression and anxiety: what do they tell us about human condition? Prog Neuropsychopharmacol Biol Psychiatry 20011; 35: 1357-1375. Go to original source... Go to PubMed...
  12. Enoch MA, White KV, Waheed J, Goldman D. Neurophysiological and genetic distinctions between pure and comorbid anxiety disorders. Depress. Anxiety 2008: 25: 383-392. Go to original source... Go to PubMed...
  13. Andreescu C, Lenze EJ. Comorbid anxiety and depression: b?te noire or quick fix? Br J Psychiatry 2012? 200: 179-181. Go to original source... Go to PubMed...
  14. Boyer P. Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatr Scand (Suppl) 2000? 406: 24-29. Go to original source...
  15. Engels AD, Heller W, Spielberg JM, et al. Co-occuring anxiety influences patterns of brain activity in depression. Cogn Affect Behav Neurosci 2010? 10: 141-156. Go to original source...
  16. Andreescu C, Butters M, Lenze EJ, et al. fMRI activation in late-life anxious depression: a potential biomarker. Int J Geriatr Psychiatry 2009? 24: 820-828. Go to original source... Go to PubMed...
  17. Češková E. Jak správně zvolit antidepresivum. Psychiatr praxi 2007; 8: 229-231.
  18. Češková E. Individualizovaná léčba deprese ve světle současných doporučených postupů. Psychiatr praxi 2008; 9: 205-208.
  19. Žourková A. Možnosti užití personalizované medicíny v léčbě depresivních poruch. Psychiatrie 2007? 11(suppl 2): 104-106. Go to original source...
  20. Anders M, Raboch, Kryl M. Depresivní porucha. V Doporučené postupy psychiatrické péče III, 127-134, Tribun EU, Brno, 1. vydání, 2010: 282.
  21. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005? 58: 175-189. Go to original source... Go to PubMed...
  22. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry 2007? 68 (suppl 10): 11-17.
  23. Rao S, Zisook S. Anxious depression: clinical features and treatment. Curr Psychiatry Rep 2009? 11: 429-436. Go to original source... Go to PubMed...
  24. Thaler K, Morgan LC, Van Noord M, et al. Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety 2012? 29: 495-505. Go to original source... Go to PubMed...
  25. Papakostas GI, Fan H, Tedeschini E. Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitor. Eur Neuropsychiatry 2012; 22: 347-355. Go to original source... Go to PubMed...
  26. Stein DJ, Ahokas AA, deBodinat C. Efficacy of agomelatine in generalized anxiety disorder. A randomized, double-blind, placebo controlled study. J Clin Psychopharmacol 2008? 28: 561-566. Go to original source... Go to PubMed...
  27. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14: 536-546. Go to original source... Go to PubMed...
  28. Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry 2011? 168: 1057-1065. Go to original source... Go to PubMed...
  29. Vulink NC, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol 2011? 21: 429-449. Go to original source... Go to PubMed...
  30. Pies R. Should psychiatrists use atypical antipsychotics to treate nonpsychotic anxiety. Psychiatry 2009? 6: 29-37. Go to original source...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.